Desvenlafaxine Tablet, Extended Release
NDC Package 72189-147-28

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Desvenlafaxine (desvenlafaxine succinate) tablets is desvenlafaxine is used to treat depression. This formulation utilizes a tablet, extended release delivery system. Marketed by Direct Rx, this product is identified by NDC 72189-147 and is authorized under FDA application ANDA204003.

Identification & Billing

NDC Package Code
72189-147-28
Package Description
28 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
11-Digit Billing Format
72189014728
RxNorm Crosswalk
  • RxCUI: 1874559 - desvenlafaxine succinate 50 MG 24HR Extended Release Oral Tablet
  • RxCUI: 1874559 - 24 HR desvenlafaxine succinate 50 MG Extended Release Oral Tablet
  • RxCUI: 1874559 - desvenlafaxine 50 MG (as desvenlafaxine succinate 76 MG) 24HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Desvenlafaxine
Non-Proprietary Name
Desvenlafaxine Succinate
Substance Name
Desvenlafaxine Succinate
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Regulatory & Marketing

Labeler Name
Direct Rx
Product Type
Human Prescription Drug
FDA Application #
ANDA204003
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-12-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72189-147-28 identifies a specific commercial package of 28 tablet, extended release in 1 bottle of Desvenlafaxine, a human prescription drug labeled by Direct Rx. This tablet, extended release is formulated for oral use and contains desvenlafaxine succinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Direct Rx on November 12, 2020. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Desvenlafaxine is used to treat depression. It may improve your mood, feelings of well-being, and energy level. Desvenlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

How is this Direct Rx product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72189014728. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72189-147-28
11-Digit CMS (5-4-2)
72189-0147-28

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.